Clin2
NCT06598007Possibly a fitRecruiting

Studying CT3001 for advanced solid tumors

Solid Tumor, AdultColorectal CancerPancreatic Ductal Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
78 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have a type of advanced solid tumor (like colon, lung, or breast cancer) that has spread or cannot be removed with surgery, and standard treatments either didn't work or aren't available.
  • You should be well enough to perform your daily activities (ECOG 0 or 1) and have a life expectancy of at least 3 months.
  • Your blood counts (hemoglobin, neutrophils, platelets) and liver/kidney function must be within certain limits.
  • You must not be pregnant or nursing, and if of childbearing potential, must use reliable contraception during the study and for 3 months after.
  • You cannot have had major surgery, certain heart conditions, severe infections, or used other investigational drugs recently.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07589205Recruiting· Phase 1
Testing IBI3028 for Advanced Solid Tumors

This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.

Tianjin, Tianjin Municipality
NCT05458219Recruiting· Phase 1
Testing an antibody-drug treatment for solid tumors

This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.

Austin, Texas
NCT06600789Recruiting· Phase 1/Phase 2
Study of CT7439 for advanced solid tumors

This trial tests a new oral targeted drug (CT7439) for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.

Dallas, Texas
NCT03943004Recruiting· Phase 1
Study drug DFP-14927 for advanced solid tumors

This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.

Los Angeles, California
NCT06349408Recruiting· Phase 1
Testing IBI3001 for advanced solid tumors

This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.

Wollongong, New South Wales
NCT06410092Recruiting· Phase 1
Safety study of FTL001 for advanced solid tumors

This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.

Beijing, Beijing Municipality

Hear when a new Solid Tumor, Adult trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.